AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
1282 health care and life sciences companies are in the directory, 519 of them in the same 11-50 employee range and 156 based in Asia-Pacific (APAC).
AdvanCell may be growing as it has recently announced the dosing of the first patient in its Phase I/II TheraPb clinical trial, which is a significant milestone in the development of its Targeted Alpha Therapy platform technology. Additionally, the company has established a collaboration with POINT Biopharma to develop lead-212 labeled radioligands, indicating an expansion of its operations and partnerships within the biotechnology and oncology industries. Furthermore, AdvanCell's engagement with the AIBN's Centre for Advanced Imaging industry partner suggests active involvement in research and development, which could contribute to its growth trajectory.
“AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies.” advancell.com.au
AdvanCell is a biotechnology company based in Asia-Pacific (APAC), with 11-50 employees, founded in 2019. Its website drew about 282 visits in the latest month measured and it has raised $14.6 million over 2 rounds.
11-50 employees · a-seeds.co.jp
11-50 employees · advancells.com
11-50 employees · 4p-pharma.com
11-50 employees · acllaboratories.com
11-50 employees · actymthera.com
11-50 employees · asip.org
11-50 employees · activmedresearch.com
11-50 employees · adarx.com
11-50 employees · artbio.com
11-50 employees · alxoncology.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.